RecruitingPhase 3NCT06625957
Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition
A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 Versus NTCB-C in Patients Who Require Parenteral Nutrition
Sponsor
Yuhan Corporation
Enrollment
60 participants
Start Date
Dec 4, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 versus NTCB-C in patients who require parenteral nutrition
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Those who are 19 years old or older at the screening visit
- Patients are expected to require PN for more than 3 days
- Patients who voluntarily signed the consent form
Exclusion Criteria5
- Patients are expected difficult to survive more than 3 days
- Patients BMI is over 30 kg/m2
- Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug
- Patients with difficult central venous line
- Patients judged to be unsuitable for this trial by investigators
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNTCB02-1
3 Days infusion
DRUGNTCB-C
3 Days infusion
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06625957